Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer...
Read moreMyriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer...
Read more- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream...
Read morePLAINVIEW, N.Y., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO) today announced that management is scheduled to...
Read moreNEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Color Star Technology Co., Ltd. (Nasdaq: ADD) ("Color Star" or the "Company"),...
Read moreSEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it has entered into separate, privately...
Read moreBOISE, Idaho, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU), announced today that it will hold its...
Read moreARK Survival Ascended’s Steam sale milestone indicates a promising expansion of the ARK franchiseCULVER CITY, Calif., Nov. 16, 2023 (GLOBE...
Read moreQuarterly revenue $6.72 billion, flat year over yearQuarterly GAAP EPS $2.38 and non-GAAP EPS $2.12, up 29 percent and 4...
Read moreDENVER, Nov. 16, 2023 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and...
Read moreFluence Appoints Ahmed Pasha as Chief Financial Officer Fluence Expects to Meet or Exceed Guidance for Fiscal Year 2023 Revenues...
Read more